sm 1 peptide has been researched along with Fatty Liver, Nonalcoholic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ai, S; Gao, Y; Long, X; Yi, Y; Yu, W; Zhao, Z | 1 |
1 other study(ies) available for sm 1 peptide and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Fumigaclavine C ameliorates liver steatosis by attenuating hepatic de novo lipogenesis via modulation of the RhoA/ROCK signaling pathway.
Topics: Animals; Ergot Alkaloids; Indole Alkaloids; Lipogenesis; Mice; Mice, Obese; Non-alcoholic Fatty Liver Disease; Signal Transduction | 2023 |